You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication

Article metrics

Article menu

Download PDFPDF

XML
Case report
Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication

 

Online download statistics by month:

Online download statistics by month: June 2020 to January 2026

AbstractFullPdf
Jun 202010310338
Jul 2020748038
Aug 2020434028
Sep 2020444451
Oct 2020282926
Nov 2020414046
Dec 202037379
Jan 2021424233
Feb 2021363622
Mar 2021414117
Apr 2021414136
May 2021545434
Jun 2021424232
Jul 2021333321
Aug 2021333321
Sep 2021454516
Oct 2021313132
Nov 2021424229
Dec 2021434510
Jan 2022293014
Feb 2022272921
Mar 2022414223
Apr 2022303116
May 2022333314
Jun 2022313213
Jul 202224248
Aug 202234349
Sep 2022373733
Oct 2022343515
Nov 2022343625
Dec 202223237
Jan 202315157
Feb 202346465
Mar 2023171811
Apr 2023121219
May 202310107
Jun 202312129
Jul 2023999
Aug 202315158
Sep 202316166
Oct 202313133
Nov 202316165
Dec 2023222213
Jan 202418199
Feb 2024171711
Mar 2024191971
Apr 202413137
May 2024171912
Jun 2024232314
Jul 2024383916
Aug 202417136
Sep 2024111110
Oct 2024181910
Nov 202423259
Dec 2024131312
Jan 2025202011
Feb 202531319
Mar 202519197
Apr 2025646413
May 202522239
Jun 2025141510
Jul 2025110
Jan 2026110
Total183218521085